Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Drug Audits: HRSA Reviewing 51 Entities In 2012

Executive Summary

In its first year of auditing 340B facilities for compliance with drug discount rules, the HHS agency is investigating 45 randomly selected entities and six “targeted” entities that are the subject of specific allegations of non-compliance. About 250 hospitals have been decertified from 340B and may have to pay back discounts to drug makers.

You may also be interested in...



HRSA Pushes Ahead On 340B Hospital Audits, Gets $6M For Oversight

The Health Resources and Services Administration is continuing to audit hospitals for 340B compliance, with 94 conducted in FY 2013 and 28 completed or begun thus far in FY 2014, and one manufacturer is being audited as well. A $6 million appropriation will help the agency expand its oversight activities.

Genentech’s 340B Discounts Making Their Mark On Product Pricing

Genentech’s 340B drugs discounts totaled $1 billion in 2012 and are growing at 20% to 25% a year, a level that has prompted management to sit up and take notice, including setting up a team to work with 340B health care providers on compliance.

340B Rule Clarifying Parameters For Discount Drug Program Is Planned By Year-End, HRSA Says

Both pharmaceutical manufacturers and 340B hospitals seek more specifics on issues such as which patients are eligible to receive deeply discounted drugs through the program, how to contract with outside pharmacies and obligations of manufacturers and eligible hospitals.

Related Content

Topics

UsernamePublicRestriction

Register

PS054585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel